Zerviate (cetirizine ophthalmic solution 0.24%)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved May 2017

Specific Treatments:

ocular itching associated with allergic conjunctivitis

Therapeutic Areas

Find Related Trials for The Following Conditions

General Information

Zerviate (cetirizine ophthalmic solution 0.24%) is a second generation antihistamine (H1 receptor antagonist) that binds competitively to histamine receptor sites to reduce swelling, itching and vasodilation. 

Zerviate is specifically indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Zerviate is supplied as a solution for topical administration. The recommended dose is one drop in each affected eye twice daily (approximately 8 hours apart).

Clinical Results

FDA Approval

The FDA approval of Zerviate was based on three randomized, double-masked, placebo-controlled, conjunctival antigen challenge (Ora-CAC model of allergic conjunctivitis) clinical trials in patients with a history of allergic conjunctivitis. Onset and duration were evaluated in two of these trials in which Zerviate demonstrated statistically and clinically significantly less ocular itching compared to placebo at 15 minutes and 8 hours after treatment.

Side Effects

Adverse effects associated with the use of Zerviate may include, but are not limited to, the following:

  • ocular hyperemia
  • instillation site pain
  • reduction in visual acuity

Mechanism of Action

Zerviate (cetirizine ophthalmic solution 0.24%) is a second generation antihistamine (H1 receptor antagonist) that binds competitively to histamine receptor sites to reduce swelling, itching and vasodilation. 

Additional Information

For additional information regarding Zerviate or ocular itching associated with allergic conjunctivitis, please visit http://www.nicox.com/